Showing posts with label ucla. Show all posts
Showing posts with label ucla. Show all posts

Tuesday, May 5, 2015

Latest Lung-Sparing Therapies, Patient Resources and “Hollywood Ending” at Pacific Meso Center’s 5th International Symposium

Dr. Robert Cameron
The Pacific Meso Center, in conjunction with The Office of Continuing Medical Education of the David Geffen School of Medicine at UCLA, held the 5th International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma on May 2nd, 2015 in Santa Monica, California. The Worthington & Caron Law Firm was proud to again be the platinum sponsor of this unique medical seminar focusing on rational treatment options for patients with pleural mesothelioma.

As in years past, the course organizer and chair of the symposium was thoracic surgeon and pleural mesothelioma specialist, Dr. Robert Cameron. An ardent supporter of rational lung-sparing treatments for pleural mesothelioma, and innovator of the pleurectomy/decortication (“PD”) surgical procedure, Dr. Cameron is the founder and director of the Comprehensive Mesothelioma Program at both the UCLA Medical Center and the West Los Angeles Veterans’ Administration Medical Center.

International Panel of Specialists Discuss Latest Treatment Developments

Dr. Walter Weder
Dr. Cameron started the program with a presentation regarding the pros and cons of extending lung-sparing surgery to include the diaphragm and pericardium. Reviewing relevant study data along with his experience treating patients at UCLA and the West Los Angeles VA, Dr. Cameron concluded that it is preferable to limit the procedure to where the tumor is already present. Resection of the diaphragm and pericardium poses a risk of spreading tumor cells distantly to the abdomen and contralateral pleura and is not necessary in most patients.

In a second presentation, Dr. Cameron addressed the potential role of vaccines as an immunotherapy agent in the treatment of malignant pleural mesothelioma. He explained how vaccines can be used to overcome the immunosuppressive microenvironment of tumor cells. He sees a potential for using vaccines before, during and/or after lung- sparing surgery for pleural mesothelioma.

Dr. Walter Weder, Head of the Division of Thoracic Surgery at the University of Zurich Hospital in Switzerland, gave a presentation on his experience in transitioning from Extra-Pleural Pneumonectomy (“EPP”) to lung-sparing PD as the preferred surgical treatment for pleural mesothelioma. He also addressed a new study at the University of Zurich exploring the efficacy of a strategy to improve local control after surgery. The study, which is in its very early stages, involves spraying a mixture of Cisplatin and fibrin intraoperatively to the tumor site.

Dr. Percy Lee
Dr. Marc de Perrot, Associate Professor of Surgery at the University of Toronto, addressed the present and future use of IMRT radiation therapy before surgery. He addressed a recent study showing encouraging results for patients with epithelial mesothelioma who received one week of hemithoracic IMRT before surgery. Dr. Perrot suggested that in future studies, the protocol should be refined to include an immunotherapy agent.

Three separate presentations regarding topics relating to adjuvant radiation therapies were presented by Dr. Percy Lee, Chief of Thoracic Radiation Oncology and member of the Comprehensive Mesothelioma Program at UCLA Medical Center, Dr. Peter Chen, Radiation Oncologist at Hoag Family Cancer Institute, and Dr. Shilpen Patel, Associate Professor at the University of Washington Medical Center. The presentations revealed that recent advancements in technology and treatment methods, including helical tomotherapy, have decreased toxicity and increased the effectiveness of adjuvant radiation therapy.

Dr. Olga Olevsky
Dr. Olga Olevsky, Oncologist and member of the Comprehensive Mesothelioma Program at UCLA, addressed recent developments in systemic therapies for pleural mesothelioma, including numerous immunotherapy treatments and treatments involving cancer stem cells. Dr. Olevsky indicated that as more systemic therapies become available, developments in identifying and correlating biomarkers may allow doctors to identify which therapy will be most effective for a given patient.

Dr. J. Andrea McCart, Associate Professor at the University of Toronto Department of Surgery, presented the results of a recent study regarding the use of virotherapy as adjuvant to debulking surgery for peritoneal mesothelioma. She also presented the results of animal studies involving the use of virotherapy in the treatment of pleural mesothelioma, concluding that the favorable results suggest that it should be developed for use in humans.

Dr. Raymond Wong
Pacific Meso Center Research Scientist Raymond Wong, PhD gave a presentation regarding the results of his study at the Pacific Meso Center Lab in Los Angeles using mesenchymal stem cells to deliver drugs to tumor cells to increase the effectiveness of immunotherapy agents. He noted the opportunity to incorporate delivery via mesenchymal stem cells with the many studies that are currently being conducted for the new PD-1 immune checkpoint blocking drugs.

Patient Resources and Advocacy

Lien Hua-Feng,
Nurse Practitioner
Lien Hua-Feng, Nurse Practitioner at the Pacific Meso Center, gave an eye-opening presentation regarding deceitful tactics employed by disreputable lawyers seizing on the vulnerability of patients diagnosed with mesothelioma. She provided examples of websites appearing to be maintained by medical professionals offering free assistance with medical treatment and contacting mesothelioma specialists. But the “disclaimer page” on the sites reveals that they are really maintained by a law firm and should not be relied upon for making medical decisions. She explained that, instead of getting reliable medical information, patients who contact the sites are besieged with calls from so-called “patient advocates” or attorneys seeking to sign them as clients. Nurse Hua-Feng warned patients of the importance of turning to “real” medical professionals for reliable medical information and experienced attorneys for reliable legal information.

Linda Reinstein, President and CEO of the Asbestos Disease Awareness Organization, gave a presentation on recent legislation regarding asbestos and the status of her ongoing efforts to get congress to enact a meaningful ban of asbestos in the United States.

“Hollywood Ending”

Clare Cameron
Pacific Meso Center Executive Director Clare Cameron gave an enlightening presentation regarding the long-standing use of asbestos in the film industry and the number of actors and production workers who have been stricken with mesothelioma. She provided shocking statistics about the amount of asbestos used in such classic movies as “Wizard of Oz,” “White Christmas” and “It’s a Wonderful Life.”

The symposium concluded with an emotional presentation from Mia Lauter, wife of actor Ed Lauter, who appeared in over 550 feature productions and lost his life to mesothelioma in 2013. She explained that when Ed was diagnosed, the only treatment options his doctor told him about were chemotherapy and amputation of his lung though EPP. Ed eventually had chemotherapy and died shortly thereafter.

Mia expressed regret over not knowing about the Pacific Meso Center at the time, and how, with information about additional treatment options such as the lung-sparing treatments available through UCLA and Dr. Cameron, Ed’s situation could have been different.

Mia and Ed Lauter
Mia is converting her grief into action to improve the outcomes of others who contract mesothelioma, both in and out of the entertainment industry. She is working with PMC to hold a fundraising gala in November at the SLS Hotel in Hollywood. Ed’s good friend and former co-star Liam Neeson has committed to participate in the event which will raise much needed funds for mesothelioma research conducted by PMC.

Mia stated that when Ed was diagnosed, he and others afflicted with mesothelioma needed a “louder voice.” Now, with her commitment to raising awareness and the need for research, mesothelioma sufferers will have a “Lauter voice!”

The Pacific Meso Center plans to release videos of the symposium presentations on its website in the coming weeks.

Wednesday, April 1, 2015

Early Bird Special! Register Now for the 5th International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma!


The 5th Annual Symposium will once again be held at the Le Méridien Delfina, on Saturday, May 2, 2015, from 8 a.m. to 5 p.m., in beautiful Santa Monica, California.

Dr. Robert Cameron, is the course organizer as well as the Director of the UCLA Mesothelioma Comprehensive Research Program.  Dr. Cameron also serves as the Chief of Thoracic Surgery at the West Los Angeles VA Medical Center and the Scientific Advisor at the Pacific Meso Center.

Dr. Cameron has over 28 years of experience with treating patients with malignant pleural mesothelioma. He is an expert in lung-sparing therapies including the pleurectomy/decortication, and a number of complementary adjuvant therapies.

The Symposium is co-hosted by UCLA and the Pacific Meso Center. Joining Dr. Cameron will be several physicians and mesothelioma advocates, including:
  • Walter Weder, MD, University of Zurich, Switzerland
  • Marc de Perrot, MD, MSc, Toronto Mesothelioma Research General Hospital
  • Shilpen Patel, MD, FACRO, University of Washington Medical Center
  • Peter V. Chen, MD, Hoag Family Cancer Institute
  • Percy Lee, MD, David Geffen School of Medicine, UCLA
  • Olga Olevsky, MD, David Geffen School of Medicine, UCLA 
  • J. Andrea McCart MD, MSc, FRCS(C), University of Toronto
  • Raymond Wong, PhD, Pacific Mesothelioma Center
  • Linda Reinstein, President/CEO and Co-Founder ADAO
The Symposium highlights the most promising medical advances in mesothelioma treatment and cutting-edge new research. Experts will also discuss methods of surgical removal, including the shift from extra-pleural pnuemonectomy to lung-sparing procedures, as well as the findings from the Surgery for Mesothelioma After Radiation Therapy (SMART) trial.


The Symposium also provides an opportunity for physicians and nurses to earn continuing medical education (CME) credit. For more information, click here or call 1-888-996-MESO (6376).

Register by April 17th to receive Early Bird pricing! To register for the symposium, click here.

For a copy of the brochure, click here.

Wednesday, March 25, 2015

UCLA Health Releases New Video Chronicling Treatment of Six-Year Meso Survivor Martha Munoz

Martha and Arturo Munoz
On March 23, 2015, UCLA Health released a new video which chronicles the medical treatment of Worthington & Caron, PC client Martha Munoz. Martha was 68 years old when she was diagnosed with malignant pleural mesothelioma in March 2009. Her husband Arturo states in the video that Martha’s doctors were giving her only 9 to 10 months to live.

In April 2009, Martha consulted with Dr. Robert Cameron, thoracic surgeon and director of the Comprehensive Mesothelioma Program at UCLA Medical Center. The video chronicles Martha’s treatment at UCLA, beginning with a lung-sparing pleurectomy/decortication surgery performed by Dr. Cameron in May 2009.

“Surgery is actually the most reliable treatment,” Dr. Cameron states in the video, “The goal is to remove all tumor we can see and take it off the lung and leave the lung in place." 

The video shows a striking comparison of radiology films of Martha’s right lung before and after the surgery. The “before” films show tumor encasing and compressing the lung, making it extremely difficult to breathe. The “after” films show all visible tumor gone and the lung expanding fully to the rib cage.


Following the surgery, Martha’s treatment included chemotherapy, state-of-the-art tomotherapy and novel cryoablation therapy which freezes and destroys new small tumors.

As Dr. Cameron explains, “Our idea is to treat this as a chronic disease, so what we do is use surgery to get rid of all the tumor we can see and use the other things like radiation, immunotherapy and cryoablation to keep it that way, just like we do with other chronic diseases that people can live a long time with.”

The video reports that six years after her diagnosis, Martha is now cancer free. “This is what you call a miracle,” says Arturo. While Martha states, “We are a very close family, and with God’s help and Dr. Cameron’s help, I can have a healthy longer life.”

To schedule an appointment with Dr. Cameron:

Contact his office at (310) 470-8980.

Dr. Cameron sees patients in consultation at his Los Angeles, California clinic located at:

Thoracic Surgery Associates
10780 Santa Monica Boulevard, Suite 100
Los Angeles, CA 90025-7613


Wednesday, August 27, 2014

The Zumwalt Mesothelioma Treatment Program - The Best Medical Plan No Veterans Know About

Secretary McDonald  - Please Notify Veterans There's No Waiting List at the Zumwalt Mesothelioma Treatment Program in Los Angeles
Zumwalt Meso
Treatment Program 
The best medical plan 
no veterans know about

San Pedro, CA -- It's upsetting to read the allegations in the news about secret wait lists, cover-ups, shabby treatment, premature deaths and a culture of apathy permeating the Department of Veterans Affairs.
What's equally upsetting is letting veterans suffer and die with either no or minimal treatment even though a qualified medical team is standing by and eager to treat them.
For months now, patients and advocates (including Lt. Colonel James G. Zumwalt, USMC (Ret.)) have been entreating former Secretary Shinseki and Under Secretary Petzel to simply notify patients and doctorswithin the vast VA network of the world-class treatment available to veterans suffering from mesothelioma as a result of service-related asbestos exposure. Now with the recent confirmation of VA Secretary Robert McDonald, veterans are optimistic of the changes being proposed but their trust has been undeniably compromised.
About a year ago, the VA Medical Center in West Los Angeles, California approved (but did not budget) the Admiral Zumwalt Mesothelioma Treatment Program. The program is headed up by Dr. Robert Cameron, a well-respected thoracic surgeon who has dedicated his life to the rational treatment of pleural mesothelioma, a cancer which disproportionately impacts US service veterans.
Dr. Cameron and his crew are eager to treat veterans. Unfortunately, despite multiple requests and promises, the VA has yet to perform the simple administrative task of updating its website and other social media about the existence of the program--notices that would alert veterans suffering from mesothelioma to the high quality treatment which is available to them. Neither the VA nor West LA VA websites even mention the program.
The mesothelioma treatment team at the West LA VA Medical Center would love to have a list of veterans to treat. But there's no list, no waiting list and no effort to educate our war heroes stricken with asbestos cancer that help is available.
According to the popular literature, about 4,000 Americans are diagnosed with mesothelioma each year. Of those, roughly a third were exposed to asbestos while serving in the Navy. It's not a stretch to surmise that at least 600 Navy veterans are diagnosed with mesothelioma every year--a diagnosis that carries a nine month life expectancy with no treatment and 11-12 months with chemotherapy only.
Mesothelioma is a rare disease and few doctors are either interested or qualified to treat it with the full arsenal of options available. It's a beautiful thing that a world-renowned surgeon like Dr. Cameron is willing to treat veterans, but it's sad that the VA has done nothing to help educate patients about his extraordinary talents.
Secretary McDonald, the request is simple: Will you please educate veterans and all caregivers within the VA system that the Zumwalt Mesothelioma Treatment Program is alive and well and eager to provide prompt, world-class treatment to veterans suffering from mesothelioma (without placing them on a long list!).
With new reports of the VA medical system's failures capturing headlines every day, what better time to finally bring attention to an area where the VA has gotten it right!
For more information, please contact Worthington & Caron (http://www.mesothel.com/) or 800-831-9399.

Wednesday, May 28, 2014

Worthington & Caron Proud to Again Sponsor the 4th Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma

On June 7 some of the leading physicians involved in the diagnosis and treatment of pleural mesothelioma will meet at the Sheraton Delfina in Santa Monica, California for the 4th Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma. The symposium will be an all-day affair and begin at 8 am.

Worthington & Caron is proud to sponsor this symposium for the fourth consecutive year.

Once again, Dr. Robert B. Cameron will lead the symposium.  In addition to being the Director of the UCLA Mesothelioma Comprehensive Research Program, Dr. Cameron also is the Chief of Thoracic Surgery at the West Los Angeles VA Medical Center and Scientific Advisor at the Pacific Meso Center.

Although the seminar is geared toward physicians, it also offers continuing medical education credit and the latest information on mesothelioma for medical students, nurses, mesothelioma patients and their families

The Symposium is co-hosted by UCLA and the Pacific Meso Center. Joining Dr. Cameron will be several physicians (both 'home-grown' and international colleagues) and mesothelioma advocates, including:

  • Olga Olevsky, MD, of UCLA Medical Center
  • Percy Lee, MD, Chief Thoracic Radiation Oncology at UCLA
  • Dr. Richard Lemen, Former Assistant Surgeon General of the United States
  • Irene I-Lan Wu, MD, UCLA Pain Management Center 
  • Joachim Aerts, MD, of Erasmus MC Cancer Institute in the Netherlands
  • Jan P. van Meerbeeck, MD of Antwerp University Hospital in Belgium,
  • Linda Reinstein, President/CEO and Co-Founder Asbestos Disease Awareness Organization,
The symposium will be divided into four sessions: Lung-Sparing Surgical Techniques, Lung-Sparing Adjuvant Therapies, Potential Future Adjuvant Therapies and Supportive Therapies.

To register for the symposium, click here.


For a copy of the brochure, click here.

Tuesday, May 20, 2014

Secretary Shinseki – Please Notify Veterans There’s No Waiting List at the Zumwalt Mesothelioma Treatment Program in Los Angeles

Dear Secretary Shinseki,

Zumwalt Meso
Treatment Program 
The best medical plan 
no veterans know about.

It’s upsetting to read the allegations in the news about secret wait lists, cover-ups, shabby treatment, premature deaths and a culture of apathy permeating the Department of Veterans Affairs.

What’s equally upsetting is letting veterans suffer and die with either no or minimal treatment even though a qualified medical team is standing by and eager to treat them.

For months now, patients and advocates (including Lt. Colonel James G. Zumwalt, USMC (Ret.)) have been entreating you and Under Secretary Petzel to simply notify patients and doctors within the vast VA network of the world-class treatment available to veterans suffering from mesothelioma as a result of service-related asbestos exposure. 

About a year ago, the VA Medical Center in West Los Angeles, California approved (but did not budget) the Admiral Zumwalt Mesothelioma Treatment Program. The program is headed up by Dr. Robert Cameron, a well-respected thoracic surgeon who has dedicated his life to the rational treatment of pleural mesothelioma, a cancer which disproportionately impacts US service veterans.

Dr. Cameron and his crew are eager to treat veterans. Unfortunately, despite multiple requests and promises, the VA has yet to perform the simple administrative task of  updating its website and other social media about the existence of the program--notices that would alert veterans suffering from mesothelioma to the high quality treatment which is available them. Neither the VA nor West LA VA websites even mention the program. Please see our letter to Dr. Dean Norman, Chief of Staff, VA Greater Los Angeles Healthcare System. 


"When a veteran is
denied care, we are 
all dishonored." 
Barack Obama, 
Aug. 2007.
The mesothelioma treatment team at the West LA VA Medical Center would love to have a list of veterans to treat. But there’s no list, no waiting list and no effort to educate our war heroes stricken with asbestos cancer that help is available.

You’ve read about the double digit number of veterans who have allegedly died while waiting to be treated.  We may never know how many veterans with mesothelioma have died after receiving no or sub-standard treatment. 

According to the popular literature, about 4,000 Americans are diagnosed with mesothelioma each year. Of those, roughly a third were exposed to asbestos while serving in the Navy. It’s not a stretch to surmise that at least 600 Navy veterans are diagnosed with mesothelioma every year--a diagnosis that carries a 9 month life expectancy with no treatment and 11-12 months with chemotherapy only.

Mesothelioma is a rare disease and few doctors are either interested or qualified to treat it with the full arsenal of options available.  It’s a beautiful thing that a world-renowned surgeon like Dr. Cameron is willing to treat veterans, but it’s sad that the VA has done nothing to help educate patients about his extraordinary talents.

Secretary Shinseki, how many vets have to die before this issue finally works its way up to the inbox in your office? We’ve been sending letters to Under Secretary Petzel as well as our representatives for several months. Now that he’s resigned in the wake of the Phoenix scandal, what will happen to those heart-felt letters from patients and their families? Who will read them? Anybody? And more importantly, what will the VA do?


Secretary Shinseki,
please include 
building the Zumwalt
Meso Program in 
your mission to 
provide better and 
more timely
care to veterans.
Secretary Shinseki, we agree with you when you say that it’s your “mission” to provide quality care to each and every veteran. You say you’re “mad as hell” about recent allegations and vow “to do better.” With a budget of $164 billion, to your credit, you haven’t blamed the missteps on a lack of money. And you’re wise to investigate the nexus, if  any, between the waiting lists, which are a fact of life in modern patient management, and premature deaths.

But we are still waiting for a response. The request is simple: Will you please educate veterans and all caregivers within the VA system that the Zumwalt Mesothelioma Treatment Program is alive and well and eager to provide prompt, world-class treatment to veterans suffering from mesothelioma (without placing them on a long list!).

With new reports of the VA medical system’s failures capturing headlines every day, what better time to finally bring attention to an area where the VA has gotten it right!


Sincerely,

Roger G. Worthington
May 20, 2014

The family of former Veteran John Johnson has pledged to help 
fund the Zumwalt Meso Program at the West LA VA.

Wednesday, March 27, 2013

UCLA Now Offering Multi-Disciplinary Clinic Where Patients Can Meet With Surgeon and Oncologist Specializing in Mesothelioma at the Same Consult

Patients who are diagnosed with mesothelioma often feel overwhelmed and stressed. An aggressive tumor has been growing in their body and time is of the essence in order to effectively treat it. But before proceeding with a treatment, many questions need to be answered:


  • Am I a candidate for surgery?
  • If so, what surgery is best for me (EPP vs. PD)?
  • Should I have chemotherapy instead of surgery?
  • Should I have chemotherapy AND surgery?
  • If so, should I have chemotherapy before or after surgery?
  • If chemotherapy, what agents should I receive?

Under typical circumstances, getting reliable answers to these questions which require input from doctors with specialized knowledge in two disciplines, surgery and oncology, can be a difficult and time-consuming process. Furthermore, because of the rarity of the disease, there are many opportunities for misinformation to de-rail the process.

As part of its Comprehensive Mesothelioma Program, which brings together doctors from various specialties in a collaborative “team” approach to treating pleural mesothelioma, UCLA is now offering a weekly multi-disciplinary clinic to help patients avoid the pit-falls, challenges and delays that are often encountered in determining a treatment plan.

Common Pit-Falls, Challenges and Delays

1.  "You’re not a candidate for surgery because the tumor is too diffuse"

Most patients are diagnosed with pleural mesothelioma via a biopsy performed at a local hospital. The surgeon performing the biopsy is often a general surgeon and, even if a thoracic surgeon, does not have significant experience in the diagnosis or treatment of mesothelioma. There are many instances where the surgeon performing the biopsy advises the patient that he or she is not a candidate for surgery because the tumor is too diffuse or has spread over most of the lung. As a result, the patient is referred only to an oncologist and is presented with chemotherapy as the only treatment option.

A similar result occurs where a pulmonologist or oncologist with limited experience treating mesothelioma reviews a CT scan revealing tumor that has spread over most of the lung and determines that the patient is not a candidate for surgery.

Doctors who specialize in the treatment of pleural mesothelioma will explain that mesothelioma is, by its very nature, a diffuse tumor which spreads throughout the thin pleural lining that  surrounds the lung. Most surgeons who specialize in treating the disease will conclude that a person is a candidate for surgery so long as the tumor remains confined to the pleural space (i.e. it has not invaded the lung or the chest wall), even though it is covering much of the lung.

2.  "Reflex" Response: Alimta/Cisplatin Chemotherapy

In 2004, the FDA approved pemetrexed (Alimta) in combination with Cisplatin for the treatment of pleural mesothelioma. Alimta/Cisplatin remains the only FDA approved chemotherapy drug combination for the treatment of mesothelioma. As a result, many general oncologists that are not experienced in treating mesothelioma reflexively prescribe Alimta/Cisplatin without informing patients about other treatment options.

Doctors more experienced in treating mesothelioma are aware that: a) the FDA’s approval of Alimta/Cisplatin was limited to “use with patients who are not eligible for surgery”, b) in pre-approval trials Alimta/Cisplatin showed only a 41% partial response rate and an increased median survival rate of only 2.8 months, with the best results seen in patients with epithelial cell-type, and c) more recent published trial data reveals that a combination of surgery, radiation, and chemotherapy is almost always associated with the longest survival times. 

Alimta/Cisplatin is administered once every three weeks for a total of six rounds. With follow-up CT-scans, the treatment process typically lasts approximately six months. With the limited response and increased survival rates, many physicians believe that this is too much time to “invest” in this particular treatment when other treatment options are available for treating this aggressive disease.

3.  "Tic-Toc" and "Can we talk?"

Even if a patient is fortunate enough to work with knowledgeable doctors who are willing to consider a full range of available non-surgical and surgical treatments, the mere act of seeing doctors from the various specialties can be extremely time-consuming.

Doctors, especially specialists, are very busy and it often takes many weeks to get an appointment. Furthermore, most experienced mesothelioma specialists will want to review all medical records and radiology scans before recommending a treatment. Some will even want to have the biopsy pathology slides re-tested by pathologists they trust in order to get an accurate read on the specific cell-type of the tumor. The burden of collecting and transmitting all of these materials frequently falls on the patient and the patient’s family.

The process of preparing for and seeing various specialists can easily take a couple of months to complete and often results in different opinions and recommendations regarding treatment. For example, an oncologist recommending chemotherapy and a surgeon recommending surgery. While the oncologist and surgeon may be in communication with the pulmonologist or internist that referred the patient, the oncologist and surgeon frequently don’t speak directly to each other. Accordingly, the patient is left to make a very important medical decision in a relative “vacuum.”

Furthermore, once a decision is made and the patient proceeds with the chosen treatment, the specialist’s involvement typically ends once the treatment is completed. The patient then returns to the pulmonologist for the next step, which is often a referral to another specialist—starting the  process all over again!

UCLA’s Multi-Disciplinary Clinic Brings Patients Together With Expert Surgeon and Oncologist to Make “Team” Decisions Regarding Treatment

In furtherance of its team approach to treating mesothelioma, UCLA’s Comprehensive Mesothelioma Program recently began offering a multi-disciplinary clinic where patients can meet with both a thoracic surgeon and an oncologist who specialize in treating pleural mesothelioma.

The multi-disciplinary clinic is offered Wednesdays at the Pacific Thoracic Surgery office located at 10780 Santa Monica Boulevard, Suite 100, in Los Angeles, California. At the clinic, patients are seen in consultation by thoracic surgeon Dr. Robert B. Cameron and oncologist Dr.Olga Olevsky .

Dr. Cameron is the director of UCLA’s Comprehensive Mesothelioma Program, chief of thoracic surgery at the West Los Angeles Veterans’ Administration Medical Center and Scientific Advisor for The Pacific Meso Center. Dr. Cameron has been treating pleural mesothelioma patients for over 20 years, is the innovator of the lung-sparing Pleurectomy/Decortication surgical procedure and is widely recognized as one of the world’s foremost experts in mesothelioma treatment and research.

Dr. Olevsky is a board certified oncologist and the oncology specialist of the UCLA Comprehensive Mesothelioma Program. She is extremely knowledgeable about the various chemotherapy agents which are producing the best results for epithelial, sarcomatoid and bi-phasic cell types of mesothelioma.

At the multi-disciplinary clinic, patients are able to meet with both Dr. Cameron and Dr. Olevsky who work together to customize a treatment plan based on such factors such as the patient’s age and condition and tumor cell type, location and staging. Patients and accompanying family members are welcomed to be part of a thorough open discussion with Dr. Cameron and Dr. Olevsky regarding surgical and chemotherapy options, as well as other treatments such as radiation, cryoablation and immunotherapy offered by the UCLA Comprehensive Mesothelioma Program. The goal is, of course, to take the guesswork and frustration out of a very complex decision making process.

For patients who decide to proceed with the treatment recommended by Dr. Cameron and Dr. Olevsky, both doctors will continue to supervise all aspects of treatment from that point forward. Patients are closely monitored with follow-up examinations every three months and are referred as necessary to other specialists that are part of the Comprehensive Mesothelioma Program.

The patient-centered approach to care provided by UCLA’s multi-disciplinary clinic is aimed to save patients time and anxiety in making informed decisions about mesothelioma treatment, allowing them to proceed with treatment as early as possible and focus on getting well.

For more information about the multi-disciplinary clinic, contact Nurse Savannah Cline of the Pacific Meso Center at (310) 478-4678 or scline@phlbi.org.

Thursday, September 20, 2012

Thermal Therapy in the Treatment of Malignant Pleural Mesothelioma

As presented by Dr. Robert Cameron at the 11th International Conference of the International Mesothelioma Interest Group (iMig)  
Boston, MA – September 11-14, 2012

Thermal therapy has been used in cancer therapy for decades and hyperthermic chemotherapy perfusion, specifically, has been used in the treatment of mesothelioma but without data as to the optimal conditions.

In a study performed at UCLA, doctors sought to define in vitro the most effective strategy for the use of thermal therapy in pleural mesothelioma. They exposed three human mesothelioma cell lines to varying hyper and hyperthermic conditions using either a standard metabolic MTS absorbance assay or a standard clonogenic (which is a microbiology technique for studying the effectiveness of specific agents on the survival and proliferation of cells). Each cell line was then expanded and exposed to varying combination of hyperthermia, hypothermia and/or chemotherapy – using chemotherapy agents cisplatin, gemicitabine, and/or pemetrexed.

Their findings show that thermal therapy appears to be most effective when using hypothermia rather than hyperthermia, and chemotherapy appears to be most effective when using two drug combinations over one individually. Click here to view this abstract.